Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/Teva settle UK Lipitor patent case

Pfizer has settled its case against Teva regarding the launch of a generic version of cholesterol lowering medication Lipitor in the UK

Pfizer has settled its case against Teva regarding the launch of a generic version of cholesterol lowering medication Lipitor (atorvastatin) in the UK.

Under the terms of the agreement Teva and the other settling parties have agreed not to sell the generic atorvastatin product in the UK before patent expiry in May 2012.

Teva said it acknowledged that Pfizer's Lipitor patent was valid and its product infringed Pfizer's rights.

Pfizer extended the drug's patent protection by six months to May 2012 in Europe, with the announcement of new paediatric data enabling the launch of a chewable grape-flavoured version of Lipitor for children in the EU by November 2011.

However, generic versions of the drug are already available in certain countries including Spain, Brazil and Mexico, with Lipitor's second quarter sales down from $2.81bn in 2010 to $2.59bn in 2011.

10th October 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Sustainability
Environment: where does the pharmaceutical industry stand?
...
The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...